Overview
- Editors:
-
-
Michael A. Tainsky
-
School of Medicine , Wayne State University, Detroit, U.S.A.
- Provides a detailed overview of the range of biomarker technologies as written by leading researchers in the field
- Useful both for researchers interested in new tumor biomarkers and physicians seeking familiarity with new technologies in the clinical setting
- Covers a wide range of biomarker assay formats and systems
- Presents alternative approaches to similar forms of biomarkers, covering a variety of detection technologies and approaches to data analysis
- Comprehensive guide to pitfalls of biomarker discovery and validation technologies
Access this book
Other ways to access
Table of contents (22 protocols)
-
- Natalie J. Serkova, Kristine Glunde
Pages 273-295
-
-
- Natalie J. Serkova, Kendra M. Hasebroock, Susan L. Kraft
Pages 315-327
-
Back Matter
Pages 329-332
About this book
Biomarkers are molecular indicators of a biological status and, as biochemical species, can be interrogated to evaluate disease status and therapeutic interventions. Biomarkers may be detectable in the blood, other body fluids, or tissues. The expectation is that the level of an informative biomarker is related to the specific type of disease present in the body. Hence, disease-relevant biomarkers can be used to measure the presence, progress, or intensity of disease. Through a variety of mechanisms, cancer cells provide the biomarker material for their own detection. Tumor biomarkers include cancer-specific mutations or changes in gene expression, both of which can result in aberrant protein expression. These variant or abundant proteins can be detectable in the circulation as the free proteins or as novel autoantibodies to those proteins, the latter indicating that the immune system can provide an exquisitely sensitive sensor of disease. Because cancer cells shed DNA in the circu- tion, an event rarely seen in healthy individuals, tumor-specific genetic changes, such as promoter methylation or gene mutations, are detectable in DNA prepared from plasma or other body fluids. Cancer-related biochemical changes often effect measurable me- bolic variations within a cell or organism. In addition, these biochemical changes result in posttranslational modification of proteins via glycosylation or phosphorylation providing a plethora of opportunity for biomarker discovery.
Reviews
From the reviews:
“This well-illustrated book is an excellent resource on nucleic acid and protein-based technologies and metabolic profiling by analytic means or mass spectroscopy as well as for study designs for tumor biomarker discovery and validation. The audience includes both researchers interested in the identification and development of new tumor biomarkers and clinicians who need to be familiar with these new technologies in order to … treat cancer patients. In addition to researchers and clinicians, students interested in tumor biomarkers will find this book extremely useful.” (Omer Iqbal, Doody’s Review Service, January, 2010)
Editors and Affiliations
-
School of Medicine , Wayne State University, Detroit, U.S.A.
Michael A. Tainsky